{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:20:46Z","timestamp":1791832846698,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","award":["University of Sydney Postgraduate Award"],"award-info":[{"award-number":["University of Sydney Postgraduate Award"]}],"id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective management of rheumatoid arthritis (RA) often requires the use of biological disease-modifying antirheumatic drugs (bDMARDs). Biosimilar drugs (biosimilars), licensed pharmaceutical products that exhibit high similarity to their reference biological products (originators), have emerged as more affordable alternatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To compare the real-world effectiveness and safety of biosimilars and originators of bDMARDs in the management of RA at treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A systematic literature search was conducted using PubMed, MEDLINE, Embase, Scopus, International Pharmaceutical Abstract and CINAHL from database inception to 18th April 2025. Observational studies utilising real-world data (e.g., electronic health records, biologics registries) that compared clinical outcomes between patients initiating treatment with either a biosimilar or an originator for RA were included. Quality assessment was conducted using the Newcastle\u2013Ottawa Scale (NOS) and a narrative synthesis was conducted to summarise key findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 13 retrospective cohort studies were included, providing data on 34,280 patients initiating treatment with bDMARDs for RA. Treatment retention was the most investigated effectiveness outcome (n\u2009=\u200911), and all studies found that biosimilars were associated with comparable retention profiles compared to originators. No significant differences were identified for other effectiveness outcomes (e.g., disease activity indices). For safety outcomes, adverse events (AEs) were documented in eight studies. However, seven of these studies were of poor quality in assessing safety outcomes due to inadequate control for confounding factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real-world settings, biosimilars generally demonstrate comparable effectiveness to originators. Future investigations are warranted to examine the comparative safety profiles of biosimilars and originators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-025-01956-6","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:51:03Z","timestamp":1750827063000},"page":"1567-1579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7758-6087","authenticated-orcid":false,"given":"Chin Hang","family":"Yiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2400-8733","authenticated-orcid":false,"given":"Grace Tsz Yan","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi Hei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6045-6937","authenticated-orcid":false,"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3907-304X","authenticated-orcid":false,"given":"Jacques","family":"Raubenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-6837","authenticated-orcid":false,"given":"Christine Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"1956_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360\u201372.","journal-title":"JAMA"},{"key":"1956_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41:863\u201377.","journal-title":"Rheumatol Int"},{"key":"1956_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73:1108\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"1956_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"1956_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"A Kerschbaumer","year":"2023","unstructured":"Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82:95\u2013106.","journal-title":"Ann Rheum Dis"},{"key":"1956_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.23512","volume":"70","author":"A Hresko","year":"2018","unstructured":"Hresko A, Lin T, Solomon DH. Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis. Arthritis Care Res. 2018;70:1431\u20138.","journal-title":"Arthritis Care Res"},{"key":"1956_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-017-0717-1","volume":"77","author":"P Declerck","year":"2017","unstructured":"Declerck P, Danesi R, Petersel D, et al. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77:671\u20137.","journal-title":"Drugs"},{"key":"1956_CR8","doi-asserted-by":"publisher","first-page":"102234","DOI":"10.1016\/j.coph.2022.102234","volume":"64","author":"CA Conran","year":"2022","unstructured":"Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022;64:102234.","journal-title":"Curr Opin Pharmacol"},{"key":"1956_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/pharmaceutics13010048","volume":"13","author":"I Gherghescu","year":"2020","unstructured":"Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2020;13:48.","journal-title":"Pharmaceutics"},{"key":"1956_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s43441-020-00112-8","volume":"54","author":"A Sharma","year":"2020","unstructured":"Sharma A, Khante S, Mahadik KR, et al. Regulatory perspective of international agencies for development of biosimilar products (monoclonal antibodies): an overview. Ther Innov Regul Sci. 2020;54:965\u201377.","journal-title":"Ther Innov Regul Sci"},{"key":"1956_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11096-021-01243-0","volume":"43","author":"B Duggan","year":"2021","unstructured":"Duggan B, Smith A, Barry M. Uptake of biosimilars for TNF-\u03b1 inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Int J Clin Pharm. 2021;43:1\u20136.","journal-title":"Int J Clin Pharm"},{"key":"1956_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jama.2018.7316","volume":"320","author":"J Yazdany","year":"2018","unstructured":"Yazdany J, Dudley RA, Lin GA, et al. Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under Medicare Part D. JAMA. 2018;320:931\u20133.","journal-title":"JAMA"},{"key":"1956_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-0981-6","volume":"18","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:1\u201312.","journal-title":"Arthritis Res Ther"},{"key":"1956_CR14","doi-asserted-by":"publisher","first-page":"e2315872","DOI":"10.1001\/jamanetworkopen.2023.15872","volume":"6","author":"AB de Oliveira","year":"2023","unstructured":"de Oliveira AB, Almeida MO, de Medeiros-Ribeiro AC, et al. Therapeutic equivalence of biosimilar and reference biologic drugs in rheumatoid arthritis: a systematic review and meta-analysis. JAMA Netw Open. 2023;6:e2315872.","journal-title":"JAMA Netw Open"},{"key":"1956_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/14397595.2021.1899591","volume":"32","author":"E Tanaka","year":"2022","unstructured":"Tanaka E, Kawahito Y, Kohno M, et al. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2022;32:74\u201386.","journal-title":"Mod Rheumatol"},{"key":"1956_CR16","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, Grosso V, Todoerti M, et al. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology. 2018;57:vii54\u20138.","journal-title":"Rheumatology"},{"key":"1956_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1742-1241.2009.02056.x","volume":"63","author":"CY Lu","year":"2009","unstructured":"Lu CY. Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract. 2009;63:691\u20137.","journal-title":"Int J Clin Pract"},{"key":"1956_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"LP Garrison","year":"2007","unstructured":"Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10:326\u201335.","journal-title":"Value Health"},{"key":"1956_CR19","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.1016\/j.jval.2018.04.1306","volume":"21","author":"S Aggarwal","year":"2018","unstructured":"Aggarwal S, Topaloglu O, Kumar S. Real world evidence for effectiveness of biologics for rheumatoid arthritis: systematic literature review of population based registry studies. Value Health. 2018;21:S192.","journal-title":"Value Health"},{"key":"1956_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11096-024-01825-8","volume":"47","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang Y, Wang M, et al. Evaluating biosimilars: safety, efficacy, and regulatory considerations in clinical studies. Int J Clin Pharm. 2025;47:232\u20136.","journal-title":"Int J Clin Pharm"},{"key":"1956_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/bcp.15101","volume":"88","author":"N Garc\u00eda-Beloso","year":"2022","unstructured":"Garc\u00eda-Beloso N, Altab\u00e1s-Gonz\u00e1lez I, Samart\u00edn-Ucha M, et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review. Br J Clin Pharmacol. 2022;88:1529\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"1956_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clinthera.2018.11.002","volume":"41","author":"G Bakalos","year":"2019","unstructured":"Bakalos G, Zintzaras E. Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review. Clin Ther. 2019;41:155\u201373.","journal-title":"Clin Ther"},{"key":"1956_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108:734\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"1956_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/14712598.2020.1812575","volume":"21","author":"J-W Kim","year":"2021","unstructured":"Kim J-W, Jung J-Y, Suh C-H. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opin Biol Ther. 2021;21:57\u201373.","journal-title":"Expert Opin Biol Ther"},{"key":"1956_CR25","doi-asserted-by":"publisher","first-page":"e001637","DOI":"10.1136\/rmdopen-2021-001637","volume":"7","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Caporali R, Doerner T, et al. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. RMD Open. 2021;7:e001637.","journal-title":"RMD Open"},{"key":"1956_CR26","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"key":"1956_CR27","unstructured":"Veritas Health Innovation. Covidence systematic review software. Melbourne: Veritas Health Innovation. https:\/\/www.covidence.org. Accessed 29 Apr 2024."},{"key":"1956_CR28","doi-asserted-by":"publisher","first-page":"927179","DOI":"10.3389\/fphar.2022.927179","volume":"13","author":"CT de Castro","year":"2022","unstructured":"de Castro CT, de Queiroz MJ, Albuquerque FC, et al. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: systematic review and meta-analysis. Front Pharmacol. 2022;13:927179.","journal-title":"Front Pharmacol"},{"key":"1956_CR29","first-page":"2398","volume":"33","author":"G Gartlehner","year":"2006","unstructured":"Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398\u2013408.","journal-title":"J Rheumatol"},{"key":"1956_CR30","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","volume":"45","author":"CG Grijalva","year":"2007","unstructured":"Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45:S66\u201376.","journal-title":"Med Care"},{"key":"1956_CR31","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1007\/s10067-023-06760-z","volume":"42","author":"CL Weinstein","year":"2023","unstructured":"Weinstein CL, Meehan AG, Lin J, et al. Long-term golimumab persistence: five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Clin Rheumatol. 2023;42:3397\u2013405.","journal-title":"Clin Rheumatol"},{"key":"1956_CR32","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. Newcastle-Ottawa quality assessment scale cohort studies. University of Ottawa; 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK99082\/bin\/appb-fm4.pdf. Accessed 6 Dec 2024."},{"key":"1956_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/mr\/roae018","volume":"34","author":"T Kawakami","year":"2024","unstructured":"Kawakami T, Masui S, Onishi A, et al. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort. Mod Rheumatol. 2024;34:1135\u201341.","journal-title":"Mod Rheumatol"},{"key":"1956_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/imj.16296","volume":"54","author":"CT Deakin","year":"2024","unstructured":"Deakin CT, Littlejohn GO, Griffiths H, et al. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings. Intern Med J. 2024;54:795\u2013801.","journal-title":"Intern Med J"},{"key":"1956_CR35","doi-asserted-by":"publisher","first-page":"989514","DOI":"10.3389\/fmed.2022.989514","volume":"9","author":"G Larid","year":"2022","unstructured":"Larid G, Baudens G, Dandurand A, et al. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: results of a retrospective French multicenter study. Front Med. 2022;9:989514.","journal-title":"Front Med"},{"key":"1956_CR36","doi-asserted-by":"publisher","first-page":"980832","DOI":"10.3389\/fphar.2022.980832","volume":"13","author":"N Carballo","year":"2022","unstructured":"Carballo N, P\u00e9rez Garc\u00eda C, Grau S, et al. Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: a cohort study. Front Pharmacol. 2022;13:980832.","journal-title":"Front Pharmacol"},{"key":"1956_CR37","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1093\/rheumatology\/kead127","volume":"62","author":"L Kearsley-Fleet","year":"2023","unstructured":"Kearsley-Fleet L, Rokad A, Tsoi M-F, et al. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA. Rheumatology. 2023;62:3849\u201357.","journal-title":"Rheumatology"},{"key":"1956_CR38","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/medicina58121851","volume":"58","author":"CC Popescu","year":"2022","unstructured":"Popescu CC, Mogo\u0219an CD, Enache L, et al. Comparison of efficacy and safety of original and biosimilar adalimumab in active rheumatoid arthritis in a real-world national cohort. Medicina (Mex). 2022;58:1851.","journal-title":"Medicina (Mex)"},{"key":"1956_CR39","unstructured":"Pinto AS, Cunha MM, Monteiro AM, et al. Effectiveness and safety of original and biosimilar etanercept (Enbrel\u00ae vs Benepali\u00ae) in bDMARD-na\u00efve patients in a real-world cohort of Portugal. ARP Rheumatol. 2022;2:109\u2013116."},{"key":"1956_CR40","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00296-017-3663-z","volume":"37","author":"Y-K Sung","year":"2017","unstructured":"Sung Y-K, Cho S-K, Kim D, et al. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Rheumatol Int. 2017;37:1007\u201314.","journal-title":"Rheumatol Int"},{"key":"1956_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/BTT.S172241","volume":"12","author":"Y Yazici","year":"2018","unstructured":"Yazici Y, Xie L, Ogbomo A, et al. A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naive Turkish population. Biol Targets Ther. 2018;12:97\u2013106.","journal-title":"Biol Targets Ther"},{"key":"1956_CR42","doi-asserted-by":"publisher","first-page":"e003531","DOI":"10.1136\/rmdopen-2023-003531","volume":"10","author":"H Jourdain","year":"2024","unstructured":"Jourdain H, Hoisnard L, Sbidian E, et al. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD Open. 2024;10:e003531.","journal-title":"RMD Open"},{"key":"1956_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biologicals.2019.10.009","volume":"62","author":"C Codreanu","year":"2019","unstructured":"Codreanu C, Popescu CC, Mogo\u0219an C, et al. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis\u2013a comparison in a real-world national cohort. Biologicals. 2019;62:27\u201332.","journal-title":"Biologicals"},{"key":"1956_CR44","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1093\/rheumatology\/keab933","volume":"61","author":"D Di Giuseppe","year":"2022","unstructured":"Di Giuseppe D, Lindstrom U, Bower H, et al. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology. 2022;61:3596\u2013605.","journal-title":"Rheumatology"},{"key":"1956_CR45","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1002\/acr.25092","volume":"75","author":"G Haugeberg","year":"2023","unstructured":"Haugeberg G, Bakland G, R\u00f8devand E, et al. Effectiveness and persistence in SB4\u2014and reference etanercept-treated rheumatoid arthritis patients in ordinary clinical practice in Norway. Arthritis Care Res. 2023;75:1986\u201395.","journal-title":"Arthritis Care Res"},{"key":"1956_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, D\u00f6rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165\u201374.","journal-title":"Ann Rheum Dis"},{"key":"1956_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/BTT.S172337","volume":"12","author":"Y Yazici","year":"2018","unstructured":"Yazici Y, Xie L, Ogbomo A, et al. Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab. Biol Targets Ther. 2018;12:127\u201334.","journal-title":"Biol Targets Ther"},{"key":"1956_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BTT.S285610","volume":"15","author":"T Fitzgerald","year":"2021","unstructured":"Fitzgerald T, Melsheimer R, Lafeuille M-H, et al. Switching and discontinuation patterns among patients stable on originator infliximab who switched to an infliximab biosimilar or remained on originator infliximab. Biol Targets Ther. 2021;15:1\u201315.","journal-title":"Biol Targets Ther"},{"key":"1956_CR49","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fphar.2019.01372","volume":"10","author":"L Colloca","year":"2019","unstructured":"Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10:1372.","journal-title":"Front Pharmacol"},{"key":"1956_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","volume":"32","author":"LE Kristensen","year":"2018","unstructured":"Kristensen LE, Alten R, Puig L, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32:397\u2013404.","journal-title":"BioDrugs"},{"key":"1956_CR51","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40259-016-0202-5","volume":"30","author":"M Beck","year":"2016","unstructured":"Beck M, Michel B, Rybarczyk-Vigouret M-C, et al. Rheumatologists\u2019 perceptions of biosimilar medicines prescription: findings from a French web-based survey. BioDrugs. 2016;30:585\u201392.","journal-title":"BioDrugs"},{"key":"1956_CR52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","volume":"31","author":"E van Overbeeke","year":"2017","unstructured":"van Overbeeke E, De Beleyr B, de Hoon J, et al. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31:447\u201359.","journal-title":"BioDrugs"},{"key":"1956_CR53","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/13696998.2021.1881525","volume":"24","author":"V Patel","year":"2021","unstructured":"Patel V, Pulungan Z, Shah A, et al. Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs. J Med Econ. 2021;24:299\u2013307.","journal-title":"J Med Econ"},{"key":"1956_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","volume":"84","author":"M de LF Divonne","year":"2017","unstructured":"de LF Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2017;84:133\u201340.","journal-title":"Joint Bone Spine"},{"key":"1956_CR55","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/cpt.857","volume":"102","author":"JM Franklin","year":"2017","unstructured":"Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102:924\u201333.","journal-title":"Clin Pharmacol Ther"},{"key":"1956_CR56","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2665-9913(23)00268-0","volume":"6","author":"GL Goll","year":"2024","unstructured":"Goll GL, Kvien TK. Biosimilar tocilizumab\u2014better access and lower cost? Lancet Rheumatol. 2024;6:e6\u20138.","journal-title":"Lancet Rheumatol"},{"key":"1956_CR57","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/S2665-9913(23)00237-0","volume":"6","author":"X Leng","year":"2024","unstructured":"Leng X, Leszczy\u0144ski P, Jeka S, et al. Comparing tocilizumab biosimilar BAT1806\/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. Lancet Rheumatol. 2024;6:e40\u201350.","journal-title":"Lancet Rheumatol"},{"key":"1956_CR58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11095-015-1790-3","volume":"33","author":"P Declerck","year":"2016","unstructured":"Declerck P, Farouk-Rezk M, Rudd PM. Biosimilarity versus manufacturing change: two distinct concepts. Pharm Res. 2016;33:261\u20138.","journal-title":"Pharm Res"},{"key":"1956_CR59","unstructured":"US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: guidance for industry, 2019. https:\/\/www.fda.gov\/media\/124907\/download. Accessed 20 Apr 2025."},{"key":"1956_CR60","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40259-020-00446-7","volume":"34","author":"DF Alvarez","year":"2020","unstructured":"Alvarez DF, Wolbink G, Cronenberger C, et al. Interchangeability of biosimilars: what level of clinical evidence is needed to support the interchangeability designation in the United States? BioDrugs. 2020;34:723\u201332.","journal-title":"BioDrugs"},{"key":"1956_CR61","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S2214-109X(22)00460-0","volume":"11","author":"S Morin","year":"2023","unstructured":"Morin S, Segafredo G, Piccolis M, et al. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. Lancet Glob Health. 2023;11:e145\u201354.","journal-title":"Lancet Glob Health"},{"key":"1956_CR62","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/acr.25099","volume":"75","author":"AR McClean","year":"2023","unstructured":"McClean AR, Cheng L, Bansback N, et al. Uptake and spending on biosimilar infliximab and etanercept after new start and switching policies in Canada: an interrupted time series analysis. Arthritis Care Res. 2023;75:2011\u201321.","journal-title":"Arthritis Care Res"},{"key":"1956_CR63","doi-asserted-by":"publisher","first-page":"E556","DOI":"10.1503\/cmaj.211478","volume":"194","author":"AR McClean","year":"2022","unstructured":"McClean AR, Law MR, Harrison M, et al. Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. CMAJ. 2022;194:E556\u201360.","journal-title":"CMAJ"},{"key":"1956_CR64","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/amajethics.2019.668","volume":"21","author":"MZ Zhai","year":"2019","unstructured":"Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21:668\u201378.","journal-title":"AMA J Ethics"},{"key":"1956_CR65","unstructured":"Center for Biosimilars. Samsung Bioepis report signals turning point for US biosimilars. https:\/\/www.centerforbiosimilars.com\/view\/samsung-bioepis-report-signals-turning-point-for-us-biosimilars. Accessed 4 May 2025."},{"key":"1956_CR66","doi-asserted-by":"publisher","first-page":"1272308","DOI":"10.1080\/20016689.2016.1272308","volume":"5","author":"C R\u00e9muzat","year":"2017","unstructured":"R\u00e9muzat C, Dorey J, Cristeau O, et al. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5:1272308.","journal-title":"J Mark Access Health Policy"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01956-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:03:39Z","timestamp":1763557419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01956-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1956"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01956-6","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}